Moderna-Merck combination cancer treatment granted speedy review in US and EU
A vaccine candidate has met its secondary endpoint in a phase IIb study, reducing the risk of distant metastasis or death.
by christian bundgaard, translated by daniel pedersen
Phase IIb results of a shared cancer vaccine candidate from Moderna and Merck (known as MSD outside North America) has impressed drug regulators enough to fast-track the drug come review.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Merck sues US, calling move to cut drug prices "extortion"
For subscribers
